OVV-01 is a genetically engineered vesicular stomatitis virus oncolytic virus designed to selectively amplify in tumor cells and express tumor-associated antigen NY-ESO-1.
This study was designed to evaluate the safety, tolerability, and efficacy of OVV-01 in patients with advanced solid tumors.
